{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:23:59Z","timestamp":1790882639483,"version":"4.1.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011495","name":"Massachusetts Life Science Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011495","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32AI007061"],"award-info":[{"award-number":["T32AI007061"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Academy of Clinical Laboratory Physicians and Scientists"},{"name":"Paul E. Strandjord Young Investigator Research Grant"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mycobacteroides abscessus is a rapidly growing non-tuberculous mycobacterium that causes chronic lung and soft tissue infections. Treatment options are severely limited. Amikacin has historically been a mainstay of combination treatment regimens. However, irreversible hearing loss and vestibular toxicity have led to a search for alternative agents. Apramycin is a novel aminoglycoside currently in Phase I clinical trials that may offer lower potential for ototoxic and renal toxic side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The goal of this study was to compare apramycin's in vitro activity with amikacin and other aminoglycosides against a large collection of M. abscessus clinical isolates, alone, and for apramycin and amikacin, in combination with clofazimine or linezolid. We also examined activity against a more limited collection of other rapidly growing mycobacteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Analysis was performed using reference broth microdilution MIC testing, inkjet printer-assisted checkerboard assays, and time\u2013kill assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Against M. abscessus, the MIC50\/90 for apramycin (2\u2005mg\/L) was one-eighth that of amikacin (16\u2005mg\/L). Plazomicin was inactive, and organisms were rarely susceptible to tobramycin. Synergy of either apramycin or amikacin with clofazimine or linezolid was not detected by checkerboard assay. In time\u2013kill studies, clofazimine modestly increased activity of apramycin and, to a lesser extent, amikacin. Apramycin and amikacin showed delayed bacterial killing that either achieved or approached a bactericidal threshold. Apramycin was similarly potent against other rapidly growing mycobacteria tested.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Apramycin exhibits more potent in vitro activity against a diverse set of M. abscessus and other rapidly growing mycobacteria than currently recommended aminoglycosides.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf433","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:54:19Z","timestamp":1762865659000},"source":"Crossref","is-referenced-by-count":3,"title":["Enhanced activity of apramycin and apramycin-based combinations against\n                    <i>Mycobacteroides abscessus<\/i>"],"prefix":"10.1093","volume":"81","author":[{"given":"Yanqin","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Pathology, Beth Israel Deaconess Medical Center , Boston, MA ,","place":["USA"]},{"name":"Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A","family":"Truelson","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beth Israel Deaconess Medical Center , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella A","family":"Stewart","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beth Israel Deaconess Medical Center , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A","family":"O'Doherty","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Northeastern University , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E","family":"Kirby","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beth Israel Deaconess Medical Center , Boston, MA ,","place":["USA"]},{"name":"Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"2026011413280312400_dkaf433-B1","doi-asserted-by":"publisher","first-page":"ofz221","DOI":"10.1093\/ofid\/ofz221","article-title":"Top questions in the diagnosis and treatment of pulmonary M. abscessus disease","volume":"6","author":"Nathavitharana","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2026011413280312400_dkaf433-B2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/jac\/dku431","article-title":"Time-kill kinetics of antibiotics active against rapidly growing mycobacteria","volume":"70","author":"Ferro","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2026011413280312400_dkaf433-B3","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026011413280312400_dkaf433-B4","doi-asserted-by":"publisher","first-page":"103652","DOI":"10.1016\/j.ebiom.2021.103652","article-title":"Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"73","author":"Becker","year":"2021","journal-title":"EBioMedicine"},{"key":"2026011413280312400_dkaf433-B5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.bcmd.2006.11.006","article-title":"Apramycin recognition by the human ribosomal decoding site","volume":"38","author":"Hermann","year":"2007","journal-title":"Blood Cells Mol Dis"},{"key":"2026011413280312400_dkaf433-B6","doi-asserted-by":"publisher","first-page":"10984","DOI":"10.1073\/pnas.1204073109","article-title":"Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin","volume":"109","author":"Matt","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026011413280312400_dkaf433-B7","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1523\/JNEUROSCI.3430-12.2013","article-title":"A novel role of cytosolic protein synthesis inhibition in aminoglycoside ototoxicity","volume":"33","author":"Francis","year":"2013","journal-title":"J Neurosci"},{"key":"2026011413280312400_dkaf433-B8","doi-asserted-by":"publisher","first-page":"e02585-17","DOI":"10.1128\/AAC.02585-17","article-title":"Efficacy of apramycin against multidrug-resistant Acinetobacter baumannii in the murine neutropenic thigh model","volume":"62","author":"Kang","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413280312400_dkaf433-B9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.4103\/ijmy.ijmy_73_18","article-title":"Antimycobacterial activity of veterinary antibiotics (Apramycin and Framycetin) against Mycobacterium abscessus: implication for patients with cystic fibrosis","volume":"7","author":"Moore","year":"2018","journal-title":"Int J Mycobacteriol"},{"key":"2026011413280312400_dkaf433-B10","doi-asserted-by":"publisher","first-page":"e0151021","DOI":"10.1128\/aac.01510-21","article-title":"Apramycin overcomes the inherent lack of antimicrobial bactericidal activity in Mycobacterium abscessus","volume":"66","author":"Selchow","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413280312400_dkaf433-B11","doi-asserted-by":"publisher","first-page":"2201541","DOI":"10.1183\/13993003.01541-2022","article-title":"The aminoglycoside-modifying enzyme Eis2 represents a new potential in vivo target for reducing antimicrobial drug resistance in Mycobacterium abscessus complex","volume":"60","author":"Lor\u00e8","year":"2022","journal-title":"Eur Respir J"},{"key":"2026011413280312400_dkaf433-B12","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1093\/jac\/dkx125","article-title":"Elucidation of Mycobacterium abscessus aminoglycoside and capreomycin resistance by targeted deletion of three putative resistance genes","volume":"72","author":"Rominski","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026011413280312400_dkaf433-B13","doi-asserted-by":"publisher","first-page":"e01353-17","DOI":"10.1128\/AAC.01353-17","article-title":"Antagonism between front-line antibiotics clarithromycin and amikacin in the treatment of Mycobacterium abscessus infections is mediated by the whiB7 gene","volume":"61","author":"Pryjma","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413280312400_dkaf433-B14","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cmi.2022.05.003","article-title":"Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia","volume":"28","author":"Aranzana-Climent","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2026011413280312400_dkaf433-B15","author":"CLSI"},{"key":"2026011413280312400_dkaf433-B16","doi-asserted-by":"publisher","first-page":"816615","DOI":"10.3389\/fcimb.2022.816615","article-title":"The use of comparative genomic analysis for the development of subspecies-specific PCR assays for Mycobacterium abscessus","volume":"12","author":"Akwani","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"2026011413280312400_dkaf433-B17","author":"CLSI"},{"key":"2026011413280312400_dkaf433-B18","doi-asserted-by":"publisher","DOI":"10.3791\/58636","article-title":"Antimicrobial synergy testing by the inkjet printer-assisted automated checkerboard array and the manual time-kill method","author":"Brennan-Krohn","year":"2019;","journal-title":"J Vis Exp"},{"key":"2026011413280312400_dkaf433-B19","doi-asserted-by":"publisher","first-page":"e00873-18","DOI":"10.1128\/AAC.00873-18","article-title":"Synergistic activity of colistin-containing combinations against colistin-resistant Enterobacteriaceae","volume":"62","author":"Brennan-Krohn","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413280312400_dkaf433-B20","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1093\/jac\/dkx241","article-title":"Screening for synergistic activity of antimicrobial combinations against carbapenem-resistant Enterobacteriaceae using inkjet printer-based technology","volume":"72","author":"Brennan-Krohn","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026011413280312400_dkaf433-B21","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1128\/JCM.00932-16","article-title":"Verification of an automated, digital dispensing platform for at-will broth microdilution-based antimicrobial susceptibility testing","volume":"54","author":"Smith","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2026011413280312400_dkaf433-B22","doi-asserted-by":"publisher","first-page":"e0182824","DOI":"10.1128\/aac.01828-24","article-title":"Triple antimicrobial combinations with potent synergistic activity against M. abscessus","volume":"69","author":"Huang","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413280312400_dkaf433-B23","author":"CLSI"},{"key":"2026011413280312400_dkaf433-B24","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/jac\/12.6.555","article-title":"Synergy with double and triple antibiotic combinations compared","volume":"12","author":"Berenbaum","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"2026011413280312400_dkaf433-B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2026011413280312400_dkaf433-B26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ijantimicag.2014.02.008","article-title":"Selection and characterisation of Staphylococcus aureus mutants with reduced susceptibility to the investigational oxazolidinone MRX-I","volume":"43","author":"Huang","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2026011413280312400_dkaf433-B27","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1093\/jac\/dkac225","article-title":"Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose","volume":"77","author":"Zhao","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026011413280312400_dkaf433-B28","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1128\/AAC.02282-15","article-title":"Amikacin pharmacokinetics\/pharmacodynamics in a novel hollow-fiber Mycobacterium abscessus disease model","volume":"60","author":"Ferro Beatriz","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413280312400_dkaf433-B29","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1128\/AAC.02448-14","article-title":"Lack of antimicrobial bactericidal activity in Mycobacterium abscessus","volume":"58","author":"Maurer","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413280312400_dkaf433-B30","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s12879-016-1689-6","article-title":"Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series","volume":"16","author":"Namkoong","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2026011413280312400_dkaf433-B31","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3390\/antibiotics11050571","article-title":"Treatment outcome in patients with Mycobacterium abscessus complex lung disease: the impact of tigecycline and amikacin","volume":"11","author":"Yang","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2026011413280312400_dkaf433-B32","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.cmi.2020.12.004","article-title":"Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice","volume":"27","author":"Becker","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2026011413280312400_dkaf433-B33","doi-asserted-by":"publisher","first-page":"6108","DOI":"10.1038\/s41598-021-85721-5","article-title":"Association between 16S rRNA gene mutations and susceptibility to amikacin in Mycobacterium avium complex and Mycobacterium abscessus clinical isolates","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"key":"2026011413280312400_dkaf433-B34","doi-asserted-by":"publisher","first-page":"e3002091","DOI":"10.1371\/journal.pbio.3002091","article-title":"Streptothricin F is a bactericidal antibiotic effective against highly drug-resistant Gram-negative bacteria that interacts with the 30S subunit of the 70S ribosome","volume":"21","author":"Morgan","year":"2023","journal-title":"PLoS Biol"},{"key":"2026011413280312400_dkaf433-B35","doi-asserted-by":"publisher","first-page":"e0322223","DOI":"10.1128\/spectrum.03222-23","article-title":"Time-dependent pharmacodynamics of amikacin on Mycobacterium abscessus growth and resistance emergence","volume":"12","author":"Gibson","year":"2024","journal-title":"Microbiol Spectr"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf433\/65612893\/dkaf433.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf433\/65612893\/dkaf433.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:28:06Z","timestamp":1768415286000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf433\/8351041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf433","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,11,28]]},"article-number":"dkaf433"}}